Zydus Pharmaceuticals (USA) Inc gets final US FDA approval to market Roflumilast tablets
Summary: Zydus, being one of the first applicants for Roflumilast Tablets, 500 mcg, is eligible for 180 days of shared generic drug…
Summary: Zydus, being one of the first applicants for Roflumilast Tablets, 500 mcg, is eligible for 180 days of shared generic drug…
Synopsis- Zydus announced today that it has received permission to initiate the Phase II (a) clinical study of its NLRP3 inhibitor “ZYIL1”…
Synopsis – The company’s subsidiary has received tentative approval from the US Food and Drug Administration (USFDA) for Cariprazine capsules in the…